千錘百煉磨出從容底氣，做新藥研發(fā)征程的“較真”守護(hù)者 | Bilingual

編者按：“讓天下沒有難做的藥，難治的病”，是初心，更是愿景。自成立以來，藥明康德步履不停：從一間實(shí)驗(yàn)室，到覆蓋亞洲、歐洲和北美的全球網(wǎng)絡(luò)。從早期的化學(xué)合成服務(wù)，到貫穿研究（R）、開發(fā)（D）和生產(chǎn)（M）的一體化平臺。從第一位客戶，到全球三十多個國家的眾多合作伙伴。不斷發(fā)展的，是規(guī)模與能力；始終堅(jiān)守的，是夢想與承諾。本系列文章將立足藥明康德一體化CRDMO平臺，系統(tǒng)講述公司不斷深化的能力和規(guī)模體系，以平臺承載信任，持續(xù)賦能客戶創(chuàng)新，共同推動更多突破性療法走向病患。

2026年初的一個清晨，陽光透過潔凈明亮的玻璃窗，灑落在藥明康德測試事業(yè)部上海生物分析部實(shí)驗(yàn)室里。精密的儀器泛著溫潤而沉靜的光澤，研究員們已各就各位，一切井然有序。與往常不同的是，這一天，實(shí)驗(yàn)室迎來了兩位特殊的“客人”——美國病理學(xué)家協(xié)會（CAP）的現(xiàn)場審計官。

實(shí)驗(yàn)室的研究員們并沒有因?qū)徲嫻俚牡絹矶騺y步調(diào)，他們熟練地調(diào)試儀器、整理試劑，電腦屏幕上跳動著項(xiàng)目進(jìn)度表，一切如常。

審計官們有條不紊地穿梭在各個實(shí)驗(yàn)臺之間，翻看記錄、詢問操作、抽查數(shù)據(jù)，全程沒有一句多余的話語。隨著各項(xiàng)檢查的推進(jìn)，他們原本緊繃的神情漸漸舒展，最終浮現(xiàn)出滿意的笑容。

當(dāng)審計官合上文件的那一刻，結(jié)果沒有意外：無嚴(yán)重發(fā)現(xiàn)項(xiàng)，順利完成審計。

審計不是考驗(yàn)，是質(zhì)量的“全面體檢”

此次完成CAP審計并非偶然。自2005年藥明康德生物分析部成立以來，實(shí)驗(yàn)室已多次通過中國國家藥品監(jiān)督管理局（NMPA，原CFDA）、美國食品藥品監(jiān)督管理局（FDA）、經(jīng)濟(jì)合作與發(fā)展組織（OECD）、歐洲藥品管理局（EMA）、美國病理學(xué)家協(xié)會（CAP）、日本醫(yī)藥品醫(yī)療器械綜合機(jī)構(gòu)（PMDA）的體系和項(xiàng)目核查。這些成果，是團(tuán)隊(duì)多年來深耕“高標(biāo)準(zhǔn)質(zhì)量體系”的有力見證。

圖片來源：123RF

當(dāng)被問及為何能每一次都高質(zhì)量完成全球權(quán)威機(jī)構(gòu)的審計時，藥明康德測試事業(yè)部生物分析部中國區(qū)負(fù)責(zé)人童瑩女士給出的回答簡潔而堅(jiān)定：“我們強(qiáng)調(diào)‘a(chǎn)ny time is ready’（隨時準(zhǔn)備著）。”

在日常工作時，生物分析團(tuán)隊(duì)始終在思考一個問題：今天完成的每一個項(xiàng)目，是否都能經(jīng)得起未來任何一次審計的檢驗(yàn)？秉持這一理念，團(tuán)隊(duì)在質(zhì)量體系設(shè)計之初就已將數(shù)據(jù)可靠性、可追溯性以及合規(guī)要求前置，并融入到日常工作的每一個環(huán)節(jié)。

在童瑩看來，審計官是來幫團(tuán)隊(duì)做“體檢”的——既能核驗(yàn)現(xiàn)有質(zhì)量體系與項(xiàng)目執(zhí)行的合規(guī)性，更能識別潛在的改進(jìn)空間。因此，生物分析團(tuán)隊(duì)一直以來都是以積極開放的心態(tài)歡迎每一次審計的到來。

這份從容，源于生物分析團(tuán)隊(duì)對細(xì)節(jié)的極致堅(jiān)守。在行業(yè)慣例或法規(guī)未作強(qiáng)制要求的環(huán)節(jié)，生物分析團(tuán)隊(duì)依然精益求精。以關(guān)鍵數(shù)據(jù)復(fù)核為例，即便部分步驟未強(qiáng)制要求雙人復(fù)核，團(tuán)隊(duì)仍主動設(shè)置該流程，牢牢守住數(shù)據(jù)準(zhǔn)確性的底線。

正是這份對細(xì)微之處也一絲不茍的堅(jiān)持，贏得了審計機(jī)構(gòu)的高度認(rèn)可。在數(shù)次OECD審計中，審計組對生物分析部成熟的GLP體系建設(shè)與高標(biāo)準(zhǔn)質(zhì)量給予了高度評價，認(rèn)為其在質(zhì)量體系、文件管理、數(shù)據(jù)記錄與歸檔等方面持續(xù)精進(jìn)，尤其認(rèn)可計算機(jī)化系統(tǒng)驗(yàn)證方面的規(guī)范性、SOP的合規(guī)性，以及記錄的透明性與可追溯性。

“只要把每一個細(xì)節(jié)堅(jiān)守到位，監(jiān)管機(jī)構(gòu)與客戶的滿意，自然水到渠成。”童瑩補(bǔ)充道。

這種對質(zhì)量的堅(jiān)守，也是整個藥明康德質(zhì)量體系的縮影。2025年，藥明康德全年接受各類質(zhì)量審計和檢查共計741次，包括680次客戶審計，56次監(jiān)管機(jī)構(gòu)檢查，以及5次獨(dú)立第三方審計，所有審計保持“無嚴(yán)重發(fā)現(xiàn)項(xiàng)”。

以“質(zhì)量源于設(shè)計”，適配全球監(jiān)管需求

從創(chuàng)立伊始，藥明康德就嚴(yán)格遵循全球高標(biāo)準(zhǔn)。面對來自不同國家和地區(qū)監(jiān)管機(jī)構(gòu)以及專業(yè)認(rèn)證組織的多元要求，生物分析部的核心競爭力之一，就在于能夠?qū)崿F(xiàn)“多標(biāo)并行、無縫適配”。

“不同機(jī)構(gòu)的審計關(guān)注點(diǎn)不同。”童瑩解釋道，“有些機(jī)構(gòu)強(qiáng)調(diào)數(shù)據(jù)完整性與臨床數(shù)據(jù)科學(xué)可靠性，有些則強(qiáng)調(diào)研究全過程的體系化，也有機(jī)構(gòu)更關(guān)注臨床檢測實(shí)驗(yàn)室的質(zhì)量控制與持續(xù)改進(jìn)。我們的質(zhì)量體系能夠確保所有項(xiàng)目都可在相應(yīng)的合規(guī)流程下運(yùn)行。”

作為藥明康德一體化CRDMO平臺的重要組成部分，生物分析部始終貫徹公司推行的“質(zhì)量源于設(shè)計（Quality by Design）”理念。這一理念并非僅停留在口號上，而是作為公司層面的核心戰(zhàn)略，深深植根于全球每一個基地的運(yùn)營實(shí)踐中。從項(xiàng)目啟動的源頭開始，高標(biāo)準(zhǔn)的質(zhì)量控制就被預(yù)先植入到每一個環(huán)節(jié)，確保整個流程經(jīng)得起隨時隨地的檢驗(yàn)。

在這一頂層設(shè)計的指引下，生物分析團(tuán)隊(duì)展現(xiàn)出全球法規(guī)適配能力。面對復(fù)雜的跨地區(qū)申報需求，團(tuán)隊(duì)堅(jiān)持“一套規(guī)則，全球通行（One Rule for All）”的原則，將FDA、NMPA、EMA等不同監(jiān)管機(jī)構(gòu)的嚴(yán)格要求，前置融入到流程設(shè)計中。例如，當(dāng)一個項(xiàng)目需要同時在亞洲、北美，以及歐洲多地申報時，生物分析團(tuán)隊(duì)能夠基于公司深厚的積淀，迅速整合出一套兼顧多方標(biāo)準(zhǔn)的檢測方案，確保項(xiàng)目在全球范圍內(nèi)合規(guī)推進(jìn)。

圖片來源：123RF

這種源自公司層面的體系優(yōu)勢，能夠?yàn)榭蛻籼峁┛煽康拇_定性。選擇藥明康德，意味著選擇了一個已經(jīng)完成全球多家權(quán)威機(jī)構(gòu)嚴(yán)格審查的成熟質(zhì)量體系。這不僅有效規(guī)避了因標(biāo)準(zhǔn)差異導(dǎo)致需補(bǔ)充實(shí)驗(yàn)的風(fēng)險，更大幅降低了審計帶來的時間不確定性，為客戶的新藥研發(fā)項(xiàng)目保駕護(hù)航。

同時，高頻次的全球?qū)徲嬕卜床噶速|(zhì)量體系的進(jìn)化。生物分析團(tuán)隊(duì)將每一次審計視為復(fù)盤與優(yōu)化的契機(jī)，通過洞悉全球監(jiān)管的最新趨勢，不斷對流程進(jìn)行“優(yōu)化”與“強(qiáng)化”。這種“接受檢驗(yàn)-復(fù)盤優(yōu)化”的正向循環(huán)，使得團(tuán)隊(duì)能夠持續(xù)為客戶提供“安心省力”的交付體驗(yàn)，真正實(shí)現(xiàn)了質(zhì)量與效率的雙重保障。

數(shù)字化賦能，讓“又快又穩(wěn)”成為常態(tài)

“又快又穩(wěn)”是客戶對藥明康德的一致贊譽(yù)。在藥明康德，速度與質(zhì)量從來不會被取舍。

談及生物分析團(tuán)隊(duì)如何實(shí)現(xiàn)“又快又穩(wěn)”，童瑩給出了團(tuán)隊(duì)的解題思路：“質(zhì)量與效率并不矛盾。以數(shù)字化為支撐，做好科學(xué)的流程設(shè)計和精細(xì)化管理，就能在嚴(yán)守質(zhì)量底線的同時實(shí)現(xiàn)效率躍升，讓‘又快又穩(wěn)’成為常態(tài)。”

在藥明康德2025年的投資者日上，生物分析團(tuán)隊(duì)的數(shù)字化提效實(shí)踐作為公司精益運(yùn)營的成果之一得到了展示。數(shù)據(jù)顯示，依托數(shù)字化管理平臺，團(tuán)隊(duì)將瓶頸環(huán)節(jié)的周轉(zhuǎn)時長降低30%，分析時長降低35%。

這背后是三項(xiàng)核心數(shù)字化舉措的落地：一是項(xiàng)目節(jié)點(diǎn)可視化，打破信息壁壘，讓團(tuán)隊(duì)實(shí)時掌握項(xiàng)目進(jìn)度；二是自動化數(shù)據(jù)流轉(zhuǎn)與審計追蹤，減少人工干預(yù)，降低人為誤差，實(shí)現(xiàn)數(shù)據(jù)全程可追溯；三是風(fēng)險預(yù)警提前介入，將過去“人工發(fā)現(xiàn)瓶頸”的被動模式，轉(zhuǎn)變?yōu)椤跋到y(tǒng)提前提示風(fēng)險”的主動模式，從源頭規(guī)避延誤。

正如童瑩女士所強(qiáng)調(diào)的：“我們的效率來自標(biāo)準(zhǔn)化和數(shù)字化，絕不是靠壓縮質(zhì)量步驟來換取的。”

比SOP更重要的，是“為什么這么做”

技術(shù)升級與系統(tǒng)打通固然關(guān)鍵，但最終仍需人來落地執(zhí)行。在業(yè)內(nèi)，“高質(zhì)量交付”早已成為藥明康德的一張名片，其背后，是全球各基地始終保持一致的質(zhì)量標(biāo)準(zhǔn)與高效的執(zhí)行能力——既能精準(zhǔn)契合全球監(jiān)管機(jī)構(gòu)的各項(xiàng)法規(guī)要求，也能全方位滿足全球客戶的核心需求。這份一致性與執(zhí)行力，除了依托自上而下的統(tǒng)一培訓(xùn)、筑牢全員質(zhì)量認(rèn)知，更離不開團(tuán)隊(duì)常態(tài)化的相互學(xué)習(xí)、經(jīng)驗(yàn)傳承與交流共進(jìn)。

童瑩坦言：“寫制度或SOP并不難，難的是讓每一位員工真正理解‘為什么必須這樣做’。理解體系背后的邏輯，才是核心。”

圖片來源：123RF

只有深刻理解制度設(shè)立的初衷，才能在環(huán)境變化時知道如何迭代優(yōu)化。這種理解并非單次培訓(xùn)就能達(dá)成，而是在生物分析團(tuán)隊(duì)日常帶教、反復(fù)研討和問題復(fù)盤過程中，逐步沉淀為團(tuán)隊(duì)共識與行為自覺。

這一理念同樣貫穿于新員工培養(yǎng)體系。為確保新員工上崗后操作穩(wěn)健、合規(guī)，團(tuán)隊(duì)建立了嚴(yán)格的熟練度測試機(jī)制：通過模擬測試與模擬項(xiàng)目進(jìn)行實(shí)操演練，各項(xiàng)指標(biāo)全部達(dá)標(biāo)后，方能獨(dú)立承接客戶項(xiàng)目。

“新員工是質(zhì)量體系的未來，我們必須守住這個入口。”童瑩補(bǔ)充道。

以科學(xué)為燈，照亮創(chuàng)新之路

當(dāng)藥明康德生物分析團(tuán)隊(duì)把高標(biāo)準(zhǔn)質(zhì)量內(nèi)化為基本功時，行業(yè)發(fā)展的浪潮也帶來了新的考驗(yàn)——新型多肽藥物、寡核苷酸藥物、XDC偶聯(lián)藥物等新分子療法的加速興起，對生物分析領(lǐng)域提出了一道新的時代課題。

這些創(chuàng)新藥物分子的相關(guān)法規(guī)與技術(shù)標(biāo)準(zhǔn)仍在完善，個別領(lǐng)域甚至處于“無現(xiàn)成標(biāo)準(zhǔn)可依”的探索階段。面對新的考驗(yàn)，團(tuán)隊(duì)牢牢把握三個原則：以科學(xué)原理為核心、以風(fēng)險控制為底線、以全球監(jiān)管趨勢為參照。

“標(biāo)準(zhǔn)可以慢慢完善，但科學(xué)邏輯不能模糊。”童瑩說，“有時監(jiān)管標(biāo)準(zhǔn)尚未出臺，但我們必須基于科學(xué)原理，設(shè)計出嚴(yán)謹(jǐn)?shù)牧鞒獭！?/p>

以一個特色生物檢測平臺為例，目前尚未有正式的生物分析方法驗(yàn)證和樣品分析技術(shù)指導(dǎo)原則，但團(tuán)隊(duì)早已從嚴(yán)要求，提前建立了嚴(yán)格的流程和內(nèi)部標(biāo)準(zhǔn)。在最近完成的一次監(jiān)管部門首次對該檢測平臺項(xiàng)目的全面審計中，實(shí)現(xiàn)了“無嚴(yán)重發(fā)現(xiàn)項(xiàng)”。

此外，在多次NMPA審計過程中，團(tuán)隊(duì)主動關(guān)注核查專家的關(guān)注重點(diǎn)與行業(yè)監(jiān)管趨勢，發(fā)掘質(zhì)量管理的優(yōu)化方向，始終確保團(tuán)隊(duì)與法規(guī)步調(diào)一致，提前布局合規(guī)管控。

“二十年前，我們在搭建質(zhì)量體系；今天，我們在用體系支持復(fù)雜創(chuàng)新。”童瑩不禁感慨道。隨著行業(yè)發(fā)展，生物分析的邊界在不斷拓展，從傳統(tǒng)藥物檢測到新型療法研發(fā)，從單一環(huán)節(jié)檢測到全流程合規(guī)管控，唯一不變的，是團(tuán)隊(duì)對質(zhì)量的極致堅(jiān)守與對科學(xué)的敬畏。

夕陽余暉灑在實(shí)驗(yàn)員們專注的臉龐上。儀器平穩(wěn)運(yùn)轉(zhuǎn)，一組組真實(shí)、可靠的數(shù)據(jù)持續(xù)生成。對他們而言，每一組嚴(yán)謹(jǐn)無誤的數(shù)據(jù)，都可能成為一款新藥成功獲批、惠及病患的關(guān)鍵支持。

在新藥研發(fā)的漫長征程中，生物分析是確保質(zhì)量的“較真”的守護(hù)者。藥明康德生物分析團(tuán)隊(duì)，以從容姿態(tài)應(yīng)對每一次檢驗(yàn)，以專業(yè)能力適配多元標(biāo)準(zhǔn)，以對細(xì)節(jié)的極致堅(jiān)守，切實(shí)踐行著公司“讓天下沒有難做的藥，難治的病”的愿景。

Confidence Behind Clean Audit Records: WuXi AppTec Bioanalytical Services as the Guardian of New Drug Bioanalysis

“Every drug can be made, and every disease can be treated.” Since 2000, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to numerous partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision. Find out how WuXi AppTec’s integrated CRDMO platform enables innovation, accelerates R&D, and advances more new therapies to patients around the world.

One morning in early 2026, sunlight streamed through pristine laboratory windows, bathing the Shanghai facilities of WuXi AppTec Bioanalytical Services (BAS). Researchers were engrossed in their work, and precision instruments operated smoothly.

What set this day apart was the arrival of two special guests: on-site auditors from the College of American Pathologists (CAP).

The researchers maintained their focus amidst the audit. They calibrated instruments and prepared reagents with practiced ease. Real-time project timelines were displayed on computer screens as they carried out routine operations.

The auditors moved freely between workstations, reviewing records, verifying procedures, and examining data with minimal unnecessary dialogue.

When the auditors closed their assessment files, the result was expected: zero critical findings and successful completion of the audit.

Treating the Audit as a "Comprehensive Check-up" on Quality

This successful CAP audit is by no means an isolated achievement. Since the establishment of WuXi AppTec Bioanalytical Services in 2005, its affiliated laboratories have repeatedly completed quality system and project-level inspections conducted by major global regulatory bodies, including the National Medical Products Administration (NMPA, formerly CFDA), the U.S. Food and Drug Administration (FDA), the Organisation for Economic Co-operation and Development (OECD), the European Medicines Agency (EMA), the College of American Pathologists (CAP), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. This string of verified accomplishments stands as a solid testament to the team’s long-term commitment to upholding rigorous quality systems.

Image source: 123RF

Asked how the team consistently meets the rigorous standards of global regulatory authorities, Ms. Ying Tong, Head of Bioanalytical Services China at WuXi Testing, stated with simple determination,"Our principle is ‘a(chǎn)ny time is ready’."

In daily operations, the Bioanalytical Services team constantly asks itself one question: Can every project completed today withstand scrutiny from any future audit?Guided by this philosophy, the team has embedded data integrity, traceability, and compliance requirements into every step of routine workflows from the very design of its quality system.

In Ying’s view, auditors are not there to “find fault”—they are reviewers conducting a “health check” that verifies the compliance of existing quality systems and project execution, while uncovering opportunities for improvement. As such, the Bioanalytical Services team has always welcomed each audit with an open, proactive mindset.

This composure also stems from the team’s strict attention to every detail. Even for procedures not mandated by industry standards or regulatory requirements, the team consistently strives for excellence. Take critical data review as an example: although dual-person verification is not obligatory for certain steps, the team has proactively incorporated this workflow to safeguard the accuracy of experimental data.

Such meticulous attention to detail has earned high recognition from regulatory bodies. During several OECD audits, the inspection team praised WuXi AppTec Bioanalytical Services for its mature GLP framework and strong quality, highlighting continuous refinement in quality systems, document management, data recording, and archiving. The inspectors particularly commended the proactive compliance of standard operating procedures (SOPs) for computerized system validation, as well as the transparency and traceability of records.

“When every detail is held to the highest standard, we earn the trust of regulators and clients,” Ying adds.

This commitment to quality is also a microcosm of the entire WuXi AppTec quality system.In 2025, the company completed a total of 741 quality audits and inspections, including 680 audits by customers, 56 inspections by regulatory authorities, and 5 audits by independent third parties—all with zero critical findings.

Quality by Design: Aligning with Global Regulatory Expectations

Since its founding, WuXi AppTec has strictly adhered to global regulations and technical guidance.A core strength of the Bioanalytical Services team is its ability to operate seamlessly under multiple regulatory frameworks and rigorous professional accreditation standards.

“Different regulators focus on different priorities,” Ying explains. “Our quality systems ensure that all projects operate under corresponding compliant workflows.”

As an integral part of WuXi AppTec’s integrated CRDMO platform, the Bioanalytical Services team deeply embodies the company’s corporate-wide strategy of Quality by Design (QbD). This philosophy is not merely a slogan, but a core corporate strategy deeply integrated into the operational practices of every global site.From project initiation, stringent quality controls are pre-built into every stage, ensuring processes remain audit-ready at all times.

Under this top-down framework, the Bioanalytical Services team demonstrates agility in adapting to global regulations.For complex cross-region filing needs, the team follows the principle of “One Rule for All”, integrating stringent requirements from the FDA, NMPA, EMA, and other agencies directly into process design.For instance, when a project requires simultaneous regulatory submissions across Asia, North America and Europe, the Bioanalytical Services team can rapidly develop a unified testing framework that aligns with multiple global standards, drawing on the company’s extensive expertise and accumulated experience. This ensures seamless, globally compliant project execution.

Image source: 123RF

This system-wide capability provides clients with greater confidence and predictability.Choosing WuXi AppTec means partnering with a mature quality framework already rigorously vetted by leading global authorities. It not only mitigates risks of repeat experiments due to divergent standards but also significantly reduces timeline uncertainty from audits—acting as a safeguard for the efficiency of clients’ drug development programs.

Meanwhile, frequent global audits in turn fuel the continuous evolution of quality systems. The Bioanalytical Services team treats each inspection as an opportunity to review and optimize workflows, streamlining and enhancing processes based on the latest regulatory expectations. This virtuous cycle of external assessment, reflection and iterative enhancement enables WuXi AppTec to deliver a reassuring, hassle-free experience for clients, achieving robust guarantees for both quality and operational efficiency.

Digital Enabling: Achieving Speed and Stability in Routine Operations

"Fast and reliable"—this is the consistent acclaim WuXi AppTec receives from its clients. At WuXi AppTec, speed and quality are not mutually exclusive.

When asked how the Bioanalytical Services team achieves this balance, Ying shares the team’s approach: “Quality and efficiency are not contradictory. Digitalization, scientific process design, and lean management enable us to uphold quality standards while boosting productivity—making speed and stability our standard model.”

At WuXi AppTec's 2025 Investor Day, the Bioanalytical Services team's digital-driven efficiency initiatives were presented as an example of the company's lean operations:through its digital management platform, WuXi AppTec Bioanalytical Services reduced turnaround times for bottleneck steps by 30% and shortened analytical durations by 35%.

These results are driven by three core digital strategies:

• Real-time visualization of project milestones, breaking down information silos and enabling full progress transparency;

• Automated data flow and audit trails, minimizing manual intervention and human error while ensuring end-to-end data traceability;

• Proactive risk early warning, shifting from a reactive “manual bottleneck detection” model to a system-driven approach that flags risks ahead of time and prevents delays at the source.

As Ying emphasizes: “Our efficiency comes from standardization and digitalization—never from compromising on quality steps.”

Beyond SOPs: Understanding the “Why”

While technological upgrades and system integration are critical, execution ultimately depends on people. WuXi AppTec’s record for high-quality delivery is built on uniformly rigorous quality standards across global sites, implemented consistently to meet both regulatory requirements and client needs. This alignment and execution are fostered through company-wide training, an established quality culture, and ongoing peer learning, knowledge sharing, and collaboration.

Ying notes: “Writing policies or SOPs is straightforward. The real challenge is helping every employee understand why these steps are mandatory.Grasping the rationale behind the system is what matters most.”

Image source: 123RF

Only when teams understand the intent of regulations can they adapt and improve as circumstances evolve. This understanding is not achieved through one-off training, but cultivated through daily mentorship, repeated discussions, and problem-solving—gradually forming internalized discipline and routine behaviors.

This philosophy also defines the new-hire development program. To ensure new staff deliver high-quality work, the Bioanalytical Services team has implemented a rigorous proficiency testing system: new-hires complete simulated assays and mock studies, and must meet all performance benchmarks before independently undertaking client-assigned work.

“New hires are the future of our quality system. We must guard this gateway,” Ying states.

Guided by Science, Illuminating the Path of Innovation

As WuXi AppTec Bioanalytical Services has integrated stringent quality requirements into its daily operational fundamentals, the tide of industry development brings new challenges. The fast-growing development of novel molecular therapies such as new types of peptides, oligonucleotides, and XDC conjugates poses new challenges for bioanalytical science.

Regulations and technical standards for these innovative drug molecules are still evolving, with a few areas remaining in an exploratory phase where no established standards exist. Facing such new challenges, the Bioanalytical Services team adheres to three principles:grounded in scientific rationale, bounded by risk control, and aligned with global regulatory expectations.

“Standards may take time to mature, but scientific logic cannot be compromised,” Ying states. “Even when formal regulations are not yet published, we design rigorous processes based on sound scientific principles.”

One example is a specialized bioanalytical platform at WuXi AppTec Bioanalytical Services, for which no formal bioanalytical method validation or sample analysis guidelines yet exist. Even so, the team proactively established rigorous internal quality standards and well-defined procedures.In a recent first comprehensive regulatory audit of this testing platform, the platform received zero critical findings.

Beyond that, during NMPA audits, the team proactively captures the key focus areas of inspectors and emerging regulatory trends to identify opportunities for optimizing quality management, ensuring the team keeps pace with evolving regulations and pre-emptively strengthens compliance controls.

“Twenty years ago, we were building quality systems. Today, we use these systems to power complex innovation,” Ying reflects. As the industry evolves, the boundaries of bioanalysis continue to expand—from traditional drug testing to novel therapeutic development, from single-stage testing to end-to-end compliance management. Throughout this journey, one thing remains unchanged: the team’s unwavering commitment to quality and respect for science.

The glow of the setting sun falls gently on the focused faces of laboratory scientists. Instruments run steadily, continuously generating authentic and reliable data sets. For the Bioanalytical Services team, every rigorously validated data point contributes to the reliable evidence package that supports the approval of a new medicine, bringing hope and light to patients suffering from disease.

On the long journey of new drug development, bioanalysis serves as a meticulous guardian safeguarding quality throughout the process. Guided by the vision of "every drug can be made, and every disease can be treated", WuXi AppTec Bioanalytical Services team meets every test with composure, adapts to diverse global standards with professional expertise, and upholds uncompromising dedication to every detail.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請?jiān)凇杆幟骺档隆刮⑿殴娞柣貜?fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。